Skip to content

Effect of pomegranate peel Extract and vitamin E in hemodialysis patients

Effect of Pomegranate peel Extract and vitamin E on Oxidative Stress, inflammatory markers, nutritional status, metabolic profile, and quality of life in Hemodialysis Patients: a randomized double-blinded placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180816040814N1
Enrollment
70
Registered
2018-10-22
Start date
2018-11-10
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease. End-stage renal disease

Interventions

Intervention 1: First intervention group: dialysis patients receiving 2 pills of pomegranate daily containing 225 mg of pomegranate juice (90 mg of elzagic acid) + 400 units of vitamin E per day. Dura

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: People who are willing to participate in the study Hemodialysis patients undergoing hemodialysis 3 times a week for at least 3 months Hemodialysis patients who have no malignancy or severe liver problems or infectious diseases Not taking supplements like vitamin E, or other anti-inflammatory and anti-oxidant supplements will be included in the study for 3 months before the intervention.

Exclusion criteria

Exclusion criteria: People who do not follow the protocol Use supplements other than complementary ones People suffering from infectious diseases, malignancy, or liver disease

Design outcomes

Primary

MeasureTime frame
Malondialdehyde(MDA). Timepoint: A week before and one week after the intervention. Method of measurement: Using the kit and instructions specified in the kit.;Oxidized low-density lipoprotein(Ox_LDL). Timepoint: A week before and one week after the intervention. Method of measurement: Using the kit and instructions specified in the kit.;CRP. Timepoint: Before and after 8-week intervention. Method of measurement: ELISA kit according to the protocol.;Interleukin 6. Timepoint: Before and after 8-week intervention. Method of measurement: ELISA kit.;TNF-alpha. Timepoint: Before and after 8-week intervention. Method of measurement: ELISA kit.;Intercellular adhesion molecule 1. Timepoint: before and after 8 week intervention. Method of measurement: ELISA kit.;Vascular cell adhesion molecule 1. Timepoint: before and after 8 week intervention. Method of measurement: ELISA kit.;P-selectin. Timepoint: before and after 8 week intervention. Method of measurement: ELISA kit.;FBS. Timepoint: Before and after 8-week intervention. Method of measurement: enzymatic methods.;?Serum cholesterol. Timepoint: Before and after 8-week intervention. Method of measurement: Enzymatic methods.

Secondary

MeasureTime frame
Quality of life. Timepoint: A week before and one week after the intervention. Method of measurement: Quality of Life is a standard and valid questionnaire for determining the quality of life, and is the most commonly recommended method in this area.;Serum triglycerid. Timepoint: Before and after 8-week intervention. Method of measurement: Enzymatic method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTina Jafari

Shahre-kord University of Medical Sciences

Tinajafari15@yahoo.com+98 38 3334 2412

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026